Clinical Trials Browser

Unknown × durvalumab × Genitourinary × Clear all

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT05429866 2023-03-08

Immunological Variables Associated to ICI Toxicity in Cancer Patients

BreastDermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

NCT04107168 2023-02-16

Microbiome Immunotherapy Toxicity and Response Evaluation

Unknown

1,800 enrolled

DermatologicGenitourinaryThoracic

Kidney Neoplasms, Lung Neoplasms, Melanoma

NCT03759496 2022-03-23

Efficacy of Durvalumab in Non-muscle-invasive Bladder Cancer

Phase 2 Unknown

39 enrolled

Genitourinary

Urinary Bladder Neoplasms, Neoplasms

NCT03824691 2021-02-25

ARCADIA

Phase 2 Unknown

122 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT03544723 2020-06-09

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

Phase 2 Unknown

40 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicLymphoidThoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Hodgkin Disease, Liver Neoplasms, Lymphoma, Melanoma, Stomach Neoplasms, Carcinoma, Merkel Cell, Neoplasms, Squamous Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Clinical Trials

RADIANT

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Microbiome Immunotherapy Toxicity and Response Evaluation

Efficacy of Durvalumab in Non-muscle-invasive Bladder Cancer

ARCADIA

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.